We're unable to sign you in at this time. Please try again in a few minutes.
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Invited Commentary |

Tramadol and Hypoglycemia One More Thing to Worry About

Lewis S. Nelson, MD1; David N. Juurlink, MD, PhD2
[+] Author Affiliations
1Emergency Medicine, New York University School of Medicine, New York, New York
2General Internal Medicine, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada
JAMA Intern Med. 2015;175(2):194-195. doi:10.1001/jamainternmed.2014.5260.
Text Size: A A A
Published online


Pain is one of the leading reasons why patients seek medical attention, and over the past 2 decades, clinicians, health care institutions, medical organizations, and regulators have become increasingly attentive to its management. Yet despite the importance of pain as a clinical entity, the well of approved pharmacologic options is shallow, consisting principally of acetaminophen, nonsteroidal anti-inflammatory drugs, and opioids, along with off-label alternatives including certain anticonvulsants, antidepressants, and a smattering of other drugs for some types of pain. However, the expectation that analgesics can significantly reduce or abolish pain is often overly optimistic and can lead to the progressive use of higher doses of stronger analgesics without a reasonable benchmark for success or failure. The subjective nature of pain, which can fluctuate and which lacks the objective quantification that many clinicians are accustomed to, further complicates this assessment. Nonpharmacologic approaches such as physical therapy, meditation, exercise, and weight loss are harder to implement than medication because they are time consuming, labor intensive, and often not covered by insurance, even though each is supported by evidence of safety and effectiveness in selected patients.

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

First Page Preview

View Large
First page PDF preview





Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.
Submit a Comment
The other reason for increase use of tramadol
Posted on December 9, 2014
Mark McConnell, MD
Conflict of Interest: None Declared
Those of us in practice for over 20 years have noticed the following:1. A well meaning, misguided effort to make \"pain\" a \"vital sign\"2. Rampant use of oxycontin and gabapentin3. Raising \"pain\" to the level of a diagnosis rather than seeking the cause of pain4. Now, this year, we are no longer to give patients refills of hydrocodoneI agree that all of these pain meds carry risk. But the administrative and clerical and phone time for patients on chronic hydrocodone has increased by a factor of 6 (now we have to write renewals every 28-30 days). I believe this is a factor in the increased use of tramadol.
Submit a Comment


Some tools below are only available to our subscribers or users with an online account.

1 Citations

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

Related Content

Customize your page view by dragging & repositioning the boxes below.

See Also...
Articles Related By Topic
Related Collections
PubMed Articles